Reports Q2 revenue $194.4M, consensus $199.4M. “The second quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a record number of new prescribers and a record number of new patients receiving treatment. Physicians increasingly recognize hypercortisolism’s true prevalence and the necessity of appropriate treatment, which has led to increased screening and diagnosis. Our financial results don’t fully reflect this surge in demand, which outpaced our specialty pharmacy vendor’s capacity. We expect improved performance by our current vendor, as well as contribution from a second pharmacy that is coming online soon, in the coming quarters and have modified our 2025 revenue guidance to $850 – $900 million,” said Joseph K. Belanoff, M.D., CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome
- Is CORT a Buy, Before Earnings?
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
- Corcept Therapeutics’ ALS Study: A Potential Game-Changer?
- Corcept Therapeutics Submits New Drug Application to FDA